Dr. Mark R. Albertini, MD

Dr. Albertini practices at University Health Services - Madison (Highland Ave) in Madison, Wisconsin.

Dr. Albertini's NPI, 1609842624, was assigned on February 28, 2006. Dr. Albertini holds Wisconsin license 26736.

Dr. Albertini's primary practice is University Health Services - Madison (Highland Ave), at 600 Highland Ave, Madison, WI 53792. The practice phone is (608) 265-1978.

Dr. Albertini's primary practice is University Health Services - Madison (Highland Ave) in Madison, Wisconsin. Dr. Albertini is also affiliated with University Hospital. The medical group on file is UW Health. Dmand AI also links Dr. Albertini to 2 more hospitals, each named with a free account. Dr. Albertini's employer is on file too: a school & student health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Albertini practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Albertini's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Albertini is licensed in Wisconsin.

CMS data shows 293 Medicare services from Dr. Albertini across 3 procedure codes in 2024, for 71 Medicare patients. Medicare paid $11,352 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 71 Medicare patients who saw Dr. Albertini in 2024. The largest group is 65 to 74, with 36 patients. 59% of them have high blood pressure, and 54% have high cholesterol. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Albertini's median patient age at 71, with 40% women.

In 2024, Dr. Albertini wrote 116 Medicare Part D claims for 18 patients. 62% of them were for generic drugs. CMS names the drug for 23 of them, across 1 drug with 11 or more claims each, at $402 in total drug cost. In 2023, CMS named 43 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Albertini for performance year 2024, reported as part of a group. Dr. Albertini accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Albertini as offering telehealth.

Dmand AI links 37 papers to Dr. Albertini, published from 2010 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Melanoma, Skin Neoplasms and T-Lymphocytes. Dr. Albertini has published most often in J Natl Compr Canc Netw. Dr. Albertini's most frequent co-authors are Jeffrey A. Sosman, MD, Paul M. Sondel, MD, PhD and Brian R. Gastman, MD.

Dmand AI links Dr. Albertini to 8 clinical trials, 4 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Carcinoma, Transitional Cell. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 1 general payment to Dr. Albertini from 1 drug or device company in 2019. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $65.